A role for checkpoint blockade immunotherapy in the treatment of prostate cancer is yet to be established, with little or no benefit of anti-CTLA-4 and/or anti-PD-1 therapies (5–11), possibly due to relatively low mutational burden and limited T-cell infiltration (12). This evidence concerns the gene PDCD1 and Familial prostate cancer.